# US 2026/0193606 A1 · Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0193606 A1
- Document ID: US20260193606A1
- Status: Published application
- Kind: A1
- Application number: 19/131,509
- Filed: 2023-11-16
- Published: 2026-07-09
- Earliest claimed: 2022-11-21
- Assignees: Iovance Biotherapeutics, Inc.
- Applicants: Iovance Biotherapeutics, Inc.
- Inventors: Michelle Simpson-Abelson
- Web page: https://patentgrep.com/patent/US20260193606A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2501/2301: Interleukin-1 (IL-1)
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2304: Interleukin-4 (IL-4)
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/2312: Interleukin-12 (IL-12)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N 2501/24: Interferons [IFN]
- C12N 2501/25: Tumour necrosing factors [TNF]
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2502/1121: Dendritic cells
- C12N 2502/30: tumour cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are methods of producing TILs via (i) pre-REP expansion steps, (ii) co-culture with dendritic cells presenting tumor-specific antigens, (iii) co-culture with tumor-derived organoids, (iv) selection of tumor-reactive TILs, and (v) rapid expansion of said -tumor-reactive TILs, or combinations thereof. Resultant therapeutics and diagnostics are similarly disclosed.

## Claims

### Claim 1

A method for enriching tumor-reactive tumor infiltrating lymphocytes (TILs), comprising:
(a) obtaining a tumor sample from a patient;
(b) dividing the tumor sample into a first portion and a second portion;
(c) performing a first expansion of a first population of TILs in the second portion of the tumor sample by culturing the second portion of the tumor sample in a first cell culture medium and IL-2 to produce a second population of TILs; and
(d) contacting the second population of TILs with tumor cells or tumor cell antigens from or derived from a tumor digest obtained by digesting the first portion of the tumor sample to generate a third population of TILs,
wherein the third population of TILs comprises a plurality of tumor reactive TILs that is enriched in comparison to the second population of TILs.

### Claim 2 (depends on 1)

The method of claim 1, wherein step (d) is performed for about 1 to about 3 days.

### Claim 3

A method for enriching tumor-reactive tumor infiltrating lymphocytes (TILs), comprising:
(a) obtaining a tumor sample from a patient;
(b) dividing the tumor sample into a first portion and a second portion;
(c) performing a first expansion of a first population of TILs in the second portion of the tumor sample by culturing the second portion of the tumor sample in a first cell culture medium and IL-2 to produce a second population of TILs; and
(d) contacting the second population of TILs with a population of mature dendritic cells (DCs) generated from culturing a population of immature DCs with tumor cells or tumor cell antigens from or derived from a tumor digest obtained by digesting the first portion of the tumor sample to generate a third population of TILs, wherein the third population of TILs comprises a plurality of tumor reactive TILs that is enriched in comparison to the second population of TILs.

### Claim 4 (depends on 3)

The method of claim 3, wherein the population of immature DCs is generated by culturing a population of monocytes in the presence of GM-CSF and IL-4.

### Claim 5 (depends on 4)

The method of claim 4, wherein the population of monocytes is obtained from PBMCs.

### Claim 6 (depends on 5)

The method of claim 5, wherein the PBMCs are obtained from the patient.

### Claim 7 (depends on 4, 5, 6)

The method of any one of claims 4-6, wherein the population of monocytes is cultured in the presence of GM-CSF and IL-4 for about 6 days.

### Claim 8 (depends on 3, 4, 5, 6, 7)

The method of any one of claims 3-7, wherein culturing the population of immature DCs in the presence of tumor cells or tumor cell antigens from or derived from the tumor digest comprises generating tumor lysate from the tumor digest and culturing the immature DCs in the presence of tumor cells or tumor cell antigens from or derived from the tumor lysate.

### Claim 9 (depends on 3, 4, 5, 6, 7, 8)

The method of any one of claims 3-8, wherein the population of immature DCs is cultured with the tumor cells of the tumor digest at a ratio of about 3:1.

### Claim 10 (depends on 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 3-9, wherein the population of immature DCs is cultured in the presence of tumor cells or tumor cell antigens from or derived from the tumor digest for about 24 hours.

### Claim 11 (depends on 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 3-10, wherein the tumor digest or tumor lysate is subjected to dead cell removal prior to being cultured with the population of immature DCs.

### Claim 12 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 3-11, wherein culturing the population of immature DCs in the presence of tumor cells or tumor cell antigens from or derived from the tumor digest is performed in the presence of TNFα, IL-6 and IL-1β.

### Claim 13 (depends on 12)

The method of claim 12, wherein the concentration of TNFα is about 2000 IU/ml.

### Claim 14 (depends on 12, 13)

The method of claim 12 or 13, wherein the concentration of IL-6 is about 2000 IU/ml.

### Claim 15 (depends on 12, 13, 14)

The method of any one of claims 12-14, wherein the concentration of IL-1β is about 400 IU/ml.

### Claim 16 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 3-15, wherein the second population of TILs are cultured with the mature DCs.

### Claim 17 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 3-16, wherein step (d) is performed for about 1-3 days.

### Claim 18

A method for enriching tumor-reactive tumor infiltrating lymphocytes (TILs), comprising:
(a) obtaining a tumor sample from a patient;
(b) dividing the tumor sample into a first portion and a second portion;
(c) performing a first expansion of a first population of TILs in the second portion of the tumor sample by culturing the second portion of the tumor sample in a first cell culture medium and IL-2 to produce a second population of TILs; and
(d) contacting the second population of TILs with organoids generated from the first portion of the tumor sample to generate a third population of TILs, wherein the third population of TILs comprises a plurality of tumor reactive TILs that is enriched in comparison to the second population of TILs.

### Claim 19 (depends on 18)

The method of claim 18, wherein generating organoids from the first portion of the tumor sample comprises digesting the first portion of the tumor sample to obtain a tumor digest and generating organoids from the tumor digest.

### Claim 20 (depends on 18, 19)

The method of claim 18 or 19, wherein generating organoids comprises:
(a) driving the first portion of the tumor sample and an unpolymerized fluid matrix material through one or more channels of a microfluidics apparatus,
i. wherein the microfluidics apparatus controls the pressure, flow rate or pressure and flow rate within the one or more channels and maintains a temperature of 20 degrees C. or less, so that tumor-derived cells or multiple tumor fragments in the tumor sample and the unpolymerized fluid matrix travel through the one or more channels in laminar flow,
(b) combining tumor-derived cells or multiple tumor fragments and the unpolymerized fluid matrix material within the microfluidics apparatus to form a plurality of droplets of unpolymerized mixture, and
(c) exposing the plurality of droplets of unpolymerized mixture to a temperature of greater than 25 degrees C. to polymerize the fluid matrix material and form the organoid.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, further comprising identifying the plurality of tumor reactive TILs in the third population of TILs.

### Claim 22 (depends on 21)

The method of claim 21, wherein identifying the plurality of tumor reactive TILs comprises determining if a TIL exhibits an activation signal identifying the TIL as tumor reactive.

### Claim 23 (depends on 22)

The method of claim 22, wherein the activation signal comprises increased and/or decreased cell surface expression of one or more proteins.

### Claim 24 (depends on 23)

The method of claim 23, wherein the one or more proteins are selected from the group consisting of: CD3, CD4, CD8, PD-1, LAG3, Tim3, TIGIT, CD103, CD39, CD134, CD137, CD25, CD69, HLA-DR, CD107a, CD40L, Ki46, CD45RA, CCR7, and KLRG1.

### Claim 25 (depends on 23, 24)

The method of claim 23 or 24, wherein the cell surface expression of the one or more proteins is determined by flow cytometry.

### Claim 26 (depends on 25)

The method of claim 25, wherein the flow cytometry is performed using a SONY FX 500, Miltenyi Tyto or Miltenyi CliniMACS flow-activated cell sorter.

### Claim 27 (depends on 22)

The method of claim 22, wherein the activation signal comprises a cell morphology.

### Claim 28 (depends on 27)

The method of claim 27, wherein the cell morphology is a flattened, rounded cell morphology.

### Claim 29 (depends on 22)

The method of claim 22, wherein the activation signal is a concentration of mitochondrial mass in proximity to the cell membrane of the TIL.

### Claim 30 (depends on 27, 28, 29)

The method of any one of claims 27-29, wherein the activation signal is determined by an imaging-based cell separation method.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 21-30, further comprising collecting the identified plurality of tumor reactive TILs.

### Claim 32 (depends on 31)

The method of claim 31, wherein collecting the plurality of tumor reactive TILs comprises separating the plurality of tumor reactive TILs from non-tumor reactive TILs in the third population of TILs.

### Claim 33 (depends on 32)

The method of claim 32, wherein the separating the plurality of tumor reactive TILs comprises removing non-tumor reactive TILs from the third population of TILs.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1-33, wherein the method further comprises performing the step of:
(e) performing a second expansion by culturing the third population of TILs or the collected plurality of tumor reactive TILs in a second cell culture medium supplemented with additional IL-2, OKT-3 and antigen-presenting cells to generate a fourth population of TILs.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the first portion of the tumor sample comprises approximately one-third of the tumor sample.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the second portion of the tumor sample comprises approximately one half of the tumor sample.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the second portion of the tumor sample comprises approximately one third of the tumor sample.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17 and/or 19-37, wherein the tumor digest undergoes 1, 2, 3, 4, 5, or 10 freeze-thaw cycles.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1-38, wherein the first portion of the tumor sample comprises at least three million cells.

### Claim 40 (depends on 34, 35, 36, 37, 38, 39)

The method of any one of claims 34-39, wherein steps (a) through (e) are performed within a period of about 17 days to about 24 days, within a period of about 18 days to about 22 days, within a period of about 20 days to about 22 days, or within a period of about 22 days.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 1-40, wherein the first cell culture medium further comprises a factor selected from the group consisting of: IL-7, IL-15, IL-21, IL-12, Leukemia Inhibitory Factor (LIF), beta fibroblast growth factor (bFGF), and combinations thereof.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 1-41, wherein the second cell culture medium further comprises a factor selected from the group consisting of: IL-7, IL-15, IL-21, IL-12, LIF, bFGF, 41BBL, OX40L, CD86, CD64, and combinations thereof.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 1-42, wherein the tumor sample is selected from the group consisting of a solid tumor, a fine needle aspirate, and a small biopsy.

### Claim 44 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 22-43, wherein the activation signal comprises an increase in secreted interferon gamma (IFNγ).

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein the cell culture medium is provided in a container selected from the group consisting of a G-container and a Xuri cellbag.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 1-45, further comprising gene-editing the second population of TILs, the third population of TILs, or the plurality of tumor reactive TILs.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A pharmaceutical composition for the treatment of cancer comprising a population of TILs generated using the methods of any one of claims 1-46 and/or the fourth population of TILs generated using the methods of any one of claims 34-46.

### Claim 48 (depends on 47)

The composition of claim 47, wherein the cancer is selected for the group consisting of melanoma, ovarian cancer, cervical cancer, non-small-cell lung cancer (NSCLC), lung cancer, bladder cancer, breast cancer, triple negative breast cancer, cancer caused by human papilloma virus, head and neck cancer (including head and neck squamous cell carcinoma (HNSCC)), renal cancer, and renal cell carcinoma.

### Claim 49 (depends on 47, 48)

The composition of claim 47 or 48, further comprising a cryopreservant.

### Claim 50 (depends on 49)

The composition of claim 49, wherein the cryopreservant comprises dimethylsulfoxide.

### Claim 51 (depends on 47, 48)

The composition of claim 47 or 48, further comprising a cryopreservant and an isotonic agent.

### Claim 52 (depends on 51)

The composition of claim 51, further comprising a cryopreservant comprising dimethylsulfoxide and an isotonic agent comprising sodium chloride, sodium gluconate, and sodium acetate.

### Claim 53 (depends on 52)

The composition of claim 52, further comprising a cryopreservant comprising dimethylsulfoxide and dextran 40 and an isotonic agent comprising sodium chloride, sodium gluconate, and sodium acetate.

### Claim 54 (depends on 47, 48, 49, 50, 51, 52, 53)

The composition of any one of claims 47-53, wherein the composition is provided in a sterile infusion bag.

### Claim 55 (depends on 47, 48, 49, 50, 51, 52, 53, 54)

The composition of any one of claims 47-54, wherein said composition is harvested using a LOVO cell processing system.

### Claim 56 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55)

The composition according to any of claims 47-55, wherein the TILs are gene-edited.
